Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1994 Mar;70(821):162–184. doi: 10.1136/pgmj.70.821.162

Liver disease.

S D Ryder 1, R Williams 1
PMCID: PMC2397865  PMID: 8183748

Full text

PDF
163

Images in this article

176Figure 7
on p.176

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agnello V., Chung R. T., Kaplan L. M. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992 Nov 19;327(21):1490–1495. doi: 10.1056/NEJM199211193272104. [DOI] [PubMed] [Google Scholar]
  2. Alberti A., Morsica G., Chemello L., Cavalletto D., Noventa F., Pontisso P., Ruol A. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet. 1992 Sep 19;340(8821):697–698. doi: 10.1016/0140-6736(92)92234-7. [DOI] [PubMed] [Google Scholar]
  3. Alexander G. J., Brahm J., Fagan E. A., Smith H. M., Daniels H. M., Eddleston A. L., Williams R. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet. 1987 Jul 11;2(8550):66–69. doi: 10.1016/s0140-6736(87)92735-8. [DOI] [PubMed] [Google Scholar]
  4. Alter H. J., Purcell R. H., Shih J. W., Melpolder J. C., Houghton M., Choo Q. L., Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989 Nov 30;321(22):1494–1500. doi: 10.1056/NEJM198911303212202. [DOI] [PubMed] [Google Scholar]
  5. Anastassakos C., Alexander G. J., Wolstencroft R. A., Avery J. A., Portmann B. C., Panayi G. S., Dumonde D. C., Eddleston A. L., Williams R. Interleukin-1 and interleukin-2 activity in chronic hepatitis B virus infection. Gastroenterology. 1988 Apr;94(4):999–1005. doi: 10.1016/0016-5085(88)90559-8. [DOI] [PubMed] [Google Scholar]
  6. André F. E., D'Hondt E., Delem A., Safary A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine. 1992;10 (Suppl 1):S160–S168. doi: 10.1016/0264-410x(92)90576-6. [DOI] [PubMed] [Google Scholar]
  7. Arima T., Nagashima H., Murakami S., Kaji C., Fujita J., Shimomura H., Tsuji T. Cloning of a cDNA associated with acute and chronic hepatitis C infection generated from patients serum RNA. Gastroenterol Jpn. 1989 Oct;24(5):540–544. doi: 10.1007/BF02773882. [DOI] [PubMed] [Google Scholar]
  8. Barbara L., Benzi G., Gaiani S., Fusconi F., Zironi G., Siringo S., Rigamonti A., Barbara C., Grigioni W., Mazziotti A. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 1992 Jul;16(1):132–137. doi: 10.1002/hep.1840160122. [DOI] [PubMed] [Google Scholar]
  9. Beasley R. P., Hwang L. Y. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis. 1984 May;4(2):113–121. doi: 10.1055/s-2008-1040651. [DOI] [PubMed] [Google Scholar]
  10. Bengmark S., Börjesson B., Hafström L. The natural history of primary carcinoma of the liver. Scand J Gastroenterol. 1971;6(4):351–355. doi: 10.3109/00365527109181132. [DOI] [PubMed] [Google Scholar]
  11. Bismuth H., Houssin D., Ornowski J., Meriggi F. Liver resections in cirrhotic patients: a Western experience. World J Surg. 1986 Apr;10(2):311–317. doi: 10.1007/BF01658152. [DOI] [PubMed] [Google Scholar]
  12. Bismuth H., Morino M., Sherlock D., Castaing D., Miglietta C., Cauquil P., Roche A. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg. 1992 Apr;163(4):387–394. doi: 10.1016/0002-9610(92)90039-t. [DOI] [PubMed] [Google Scholar]
  13. Bressac B., Kew M., Wands J., Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991 Apr 4;350(6317):429–431. doi: 10.1038/350429a0. [DOI] [PubMed] [Google Scholar]
  14. Brettler D. B., Mannucci P. M., Gringeri A., Rasko J. E., Forsberg A. D., Rumi M. G., Garsia R. J., Rickard K. A., Colombo M. The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: an international, multicenter study. Blood. 1992 Jul 15;80(2):540–543. [PubMed] [Google Scholar]
  15. Brown J. L., Carman W. F., Thomas H. C. The clinical significance of molecular variation within the hepatitis B virus genome. Hepatology. 1992 Jan;15(1):144–148. doi: 10.1002/hep.1840150124. [DOI] [PubMed] [Google Scholar]
  16. Bruguera M., Cremades M., Salinas R., Costa J., Grau M., Sans J. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J Clin Gastroenterol. 1992 Jan;14(1):27–30. doi: 10.1097/00004836-199201000-00007. [DOI] [PubMed] [Google Scholar]
  17. Bruix J., Barrera J. M., Calvet X., Ercilla G., Costa J., Sanchez-Tapias J. M., Ventura M., Vall M., Bruguera M., Bru C. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet. 1989 Oct 28;2(8670):1004–1006. doi: 10.1016/s0140-6736(89)91015-5. [DOI] [PubMed] [Google Scholar]
  18. Brunetto M. R., Stemler M., Bonino F., Schodel F., Oliveri F., Rizzetto M., Verme G., Will H. A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. J Hepatol. 1990 Mar;10(2):258–261. doi: 10.1016/0168-8278(90)90062-v. [DOI] [PubMed] [Google Scholar]
  19. Bukh J., Purcell R. H., Miller R. H. Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):187–191. doi: 10.1073/pnas.89.1.187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Calne R. Y., Rolles K., White D. J., Thiru S., Evans D. B., McMaster P., Dunn D. C., Craddock G. N., Henderson R. G., Aziz S. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979 Nov 17;2(8151):1033–1036. doi: 10.1016/s0140-6736(79)92440-1. [DOI] [PubMed] [Google Scholar]
  21. Calvet X., Bruix J., Ginés P., Bru C., Solé M., Vilana R., Rodés J. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology. 1990 Oct;12(4 Pt 1):753–760. doi: 10.1002/hep.1840120422. [DOI] [PubMed] [Google Scholar]
  22. Carlson J. A., Rogers B. B., Sifers R. N., Finegold M. J., Clift S. M., DeMayo F. J., Bullock D. W., Woo S. L. Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice. J Clin Invest. 1989 Apr;83(4):1183–1190. doi: 10.1172/JCI113999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Carman W. F., Jacyna M. R., Hadziyannis S., Karayiannis P., McGarvey M. J., Makris A., Thomas H. C. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 1989 Sep 9;2(8663):588–591. doi: 10.1016/s0140-6736(89)90713-7. [DOI] [PubMed] [Google Scholar]
  24. Carman W. F., Zanetti A. R., Karayiannis P., Waters J., Manzillo G., Tanzi E., Zuckerman A. J., Thomas H. C. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990 Aug 11;336(8711):325–329. doi: 10.1016/0140-6736(90)91874-a. [DOI] [PubMed] [Google Scholar]
  25. Carr B. I., Selby R., Madariaga J., Iwatsuki S., Starzl T. E. Prolonged survival after liver transplantation and cancer chemotherapy for advanced-stage hepatocellular carcinoma. Transplant Proc. 1993 Feb;25(1 Pt 2):1128–1129. [PMC free article] [PubMed] [Google Scholar]
  26. Catterall A. P., Murray-Lyon I. M. Strategies for hepatitis B immunisation. Gut. 1992 May;33(5):576–579. doi: 10.1136/gut.33.5.576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Cedrone A., Rapaccini G. L., Pompili M., Grattagliano A., Aliotta A., Trombino C. Neoplastic seeding complicating percutaneous ethanol injection for treatment of hepatocellular carcinoma. Radiology. 1992 Jun;183(3):787–788. doi: 10.1148/radiology.183.3.1316621. [DOI] [PubMed] [Google Scholar]
  28. Chen P. L., Chen Y. M., Bookstein R., Lee W. H. Genetic mechanisms of tumor suppression by the human p53 gene. Science. 1990 Dec 14;250(4987):1576–1580. doi: 10.1126/science.2274789. [DOI] [PubMed] [Google Scholar]
  29. Chlebowski R. T., Brzechwa-Adjukiewicz A., Cowden A., Block J. B., Tong M., Chan K. K. Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep. 1984 Mar;68(3):487–491. [PubMed] [Google Scholar]
  30. Choo Q. L., Kuo G., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989 Apr 21;244(4902):359–362. doi: 10.1126/science.2523562. [DOI] [PubMed] [Google Scholar]
  31. Choo Q. L., Weiner A. J., Overby L. R., Kuo G., Houghton M., Bradley D. W. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull. 1990 Apr;46(2):423–441. doi: 10.1093/oxfordjournals.bmb.a072408. [DOI] [PubMed] [Google Scholar]
  32. Christopherson W. M., Mays E. T., Barrows G. H. Liver tumors in women on contraceptive steroids. Obstet Gynecol. 1975 Aug;46(2):221–223. [PubMed] [Google Scholar]
  33. Chu C. M., Liaw Y. F. Studies on the composition of the mononuclear cell infiltrates in liver from patients with chronic active delta hepatitis. Hepatology. 1989 Dec;10(6):911–915. doi: 10.1002/hep.1840100603. [DOI] [PubMed] [Google Scholar]
  34. Colapinto R. F., Stronell R. D., Birch S. J., Langer B., Blendis L. M., Greig P. D., Gilas T. Creation of an intrahepatic portosystemic shunt with a Grüntzig balloon catheter. Can Med Assoc J. 1982 Feb 1;126(3):267–268. [PMC free article] [PubMed] [Google Scholar]
  35. Colapinto R. F., Stronell R. D., Gildiner M., Ritchie A. C., Langer B., Taylor B. R., Blendis L. M. Formation of intrahepatic portosystemic shunts using a balloon dilatation catheter: preliminary clinical experience. AJR Am J Roentgenol. 1983 Apr;140(4):709–714. doi: 10.2214/ajr.140.4.709. [DOI] [PubMed] [Google Scholar]
  36. Colombato L. A., Albillos A., Groszmann R. J. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats. Hepatology. 1992 Feb;15(2):323–328. doi: 10.1002/hep.1840150224. [DOI] [PubMed] [Google Scholar]
  37. Colombo M., Kuo G., Choo Q. L., Donato M. F., Del Ninno E., Tommasini M. A., Dioguardi N., Houghton M. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet. 1989 Oct 28;2(8670):1006–1008. doi: 10.1016/s0140-6736(89)91016-7. [DOI] [PubMed] [Google Scholar]
  38. Cossar J. H., Reid D. Not all travellers need immunoglobulin for hepatitis A. Br Med J (Clin Res Ed) 1987 Jun 13;294(6586):1503–1503. doi: 10.1136/bmj.294.6586.1503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Davies S. E., Portmann B. C., O'Grady J. G., Aldis P. M., Chaggar K., Alexander G. J., Williams R. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology. 1991 Jan;13(1):150–157. [PubMed] [Google Scholar]
  40. Davison F., Alexander G. J., Trowbridge R., Fagan E. A., Williams R. Detection of hepatitis B virus DNA in spermatozoa, urine, saliva and leucocytes, of chronic HBsAg carriers. A lack of relationship with serum markers of replication. J Hepatol. 1987 Feb;4(1):37–44. doi: 10.1016/s0168-8278(87)80007-7. [DOI] [PubMed] [Google Scholar]
  41. Demetris A. J., Fung J. J., Todo S., McCauley J., Jain A., Takaya S., Alessiani M., Abu-Elmagd K., Van Thiel D. H., Starzl T. E. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation. 1992 May;53(5):1056–1062. doi: 10.1097/00007890-199205000-00017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Di Bisceglie A. M., Goodman Z. D., Ishak K. G., Hoofnagle J. H., Melpolder J. J., Alter H. J. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology. 1991 Dec;14(6):969–974. doi: 10.1016/0270-9139(91)90113-a. [DOI] [PubMed] [Google Scholar]
  43. Di Bisceglie A. M., Shindo M., Fong T. L., Fried M. W., Swain M. G., Bergasa N. V., Axiotis C. A., Waggoner J. G., Park Y., Hoofnagle J. H. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology. 1992 Sep;16(3):649–654. doi: 10.1002/hep.1840160307. [DOI] [PubMed] [Google Scholar]
  44. Dickson E. R., Murtaugh P. A., Wiesner R. H., Grambsch P. M., Fleming T. R., Ludwig J., LaRusso N. F., Malinchoc M., Chapman R. W., Kaplan M. M. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology. 1992 Dec;103(6):1893–1901. doi: 10.1016/0016-5085(92)91449-e. [DOI] [PubMed] [Google Scholar]
  45. Dittmann S., Roggendorf M., Dürkop J., Wiese M., Lorbeer B., Deinhardt F. Long-term persistence of hepatitis C virus antibodies in a single source outbreak. J Hepatol. 1991 Nov;13(3):323–327. doi: 10.1016/0168-8278(91)90076-n. [DOI] [PubMed] [Google Scholar]
  46. Donahue J. G., Muñoz A., Ness P. M., Brown D. E., Jr, Yawn D. H., McAllister H. A., Jr, Reitz B. A., Nelson K. E. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med. 1992 Aug 6;327(6):369–373. doi: 10.1056/NEJM199208063270601. [DOI] [PubMed] [Google Scholar]
  47. Dooley J. S., Vergalla J., Hoofnagle J. H., Zoon K. C., Munson P. J., Jones E. A. Specific binding of human alpha interferon to high-affinity cell-surface binding sites on peripheral blood mononuclear cells. J Lab Clin Med. 1989 May;113(5):623–631. [PubMed] [Google Scholar]
  48. Doong S. L., Tsai C. H., Schinazi R. F., Liotta D. C., Cheng Y. C. Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8495–8499. doi: 10.1073/pnas.88.19.8495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Dusheiko G., Dibisceglie A., Bowyer S., Sachs E., Ritchie M., Schoub B., Kew M. Recombinant leukocyte interferon treatment of chronic hepatitis B. Hepatology. 1985 Jul-Aug;5(4):556–560. doi: 10.1002/hep.1840050406. [DOI] [PubMed] [Google Scholar]
  50. Eriksson S. Alpha 1-antitrypsin deficiency and liver cirrhosis in adults. An analysis of 35 Swedish autopsied cases. Acta Med Scand. 1987;221(5):461–467. [PubMed] [Google Scholar]
  51. Eriksson S., Larsson C. Purification and partial characterization of pas-positive inclusion bodies from the liver in alpha 1-antitrypsin deficiency. N Engl J Med. 1975 Jan 23;292(4):176–180. doi: 10.1056/NEJM197501232920403. [DOI] [PubMed] [Google Scholar]
  52. Farinati F., De Maria N., Fornasiero A., Salvagnini M., Fagiuoli S., Chiaramonte M., Naccarato R. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig Dis Sci. 1992 May;37(5):659–662. doi: 10.1007/BF01296419. [DOI] [PubMed] [Google Scholar]
  53. Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990 Jun 1;61(5):759–767. doi: 10.1016/0092-8674(90)90186-i. [DOI] [PubMed] [Google Scholar]
  54. Feinstone S. M., Daemer R. J., Gust I. D., Purcell R. H. Live attenuated vaccine for hepatitis A. Dev Biol Stand. 1983;54:429–432. [PubMed] [Google Scholar]
  55. Feinstone S. M., Kapikian A. Z., Purceli R. H. Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science. 1973 Dec 7;182(4116):1026–1028. doi: 10.1126/science.182.4116.1026. [DOI] [PubMed] [Google Scholar]
  56. Feitelson M. A., Clayton M. M. X antigen/antibody markers in hepadnavirus infections. Antibodies to the X gene product(s). Gastroenterology. 1990 Aug;99(2):500–507. doi: 10.1016/0016-5085(90)91033-3. [DOI] [PubMed] [Google Scholar]
  57. Feitelson M. A. Products of the "X" gene in hepatitis B and related viruses. Hepatology. 1986 Mar-Apr;6(2):191–198. doi: 10.1002/hep.1840060207. [DOI] [PubMed] [Google Scholar]
  58. Ferrari C., Mondelli M. U., Penna A., Fiaccadori F., Chisari F. V. Functional characterization of cloned intrahepatic, hepatitis B virus nucleoprotein-specific helper T cell lines. J Immunol. 1987 Jul 15;139(2):539–544. [PubMed] [Google Scholar]
  59. Ferrari C., Penna A., Giuberti T., Tong M. J., Ribera E., Fiaccadori F., Chisari F. V. Intrahepatic, nucleocapsid antigen-specific T cells in chronic active hepatitis B. J Immunol. 1987 Sep 15;139(6):2050–2058. [PubMed] [Google Scholar]
  60. Ferrell L. D., Wright T. L., Roberts J., Ascher N., Lake J. Hepatitis C viral infection in liver transplant recipients. Hepatology. 1992 Oct;16(4):865–876. doi: 10.1002/hep.1840160403. [DOI] [PubMed] [Google Scholar]
  61. Flehmig B., Heinricy U., Pfisterer M. Immunogenicity of a killed hepatitis A vaccine in seronegative volunteers. Lancet. 1989 May 13;1(8646):1039–1041. doi: 10.1016/s0140-6736(89)92443-4. [DOI] [PubMed] [Google Scholar]
  62. Forbes A., Williams R. Changing epidemiology and clinical aspects of hepatitis A. Br Med Bull. 1990 Apr;46(2):303–318. doi: 10.1093/oxfordjournals.bmb.a072400. [DOI] [PubMed] [Google Scholar]
  63. Fornaciari G., Bassi C., Beltrami M., Castagnetti E., Maccari S., Plancher A. C. Hemolytic anemia secondary to interferon treatment for chronic B hepatitis. J Clin Gastroenterol. 1991 Oct;13(5):596–597. [PubMed] [Google Scholar]
  64. Francavilla A., Polimeno L., DiLeo A., Barone M., Ove P., Coetzee M., Eagon P., Makowka L., Ambrosino G., Mazzaferro V. The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro. Hepatology. 1989 Apr;9(4):614–620. doi: 10.1002/hep.1840090417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Fried M. W., Shindo M., Fong T. L., Fox P. C., Hoofnagle J. H., Di Bisceglie A. M. Absence of hepatitis C viral RNA from saliva and semen of patients with chronic hepatitis C. Gastroenterology. 1992 Apr;102(4 Pt 1):1306–1308. [PubMed] [Google Scholar]
  66. Fujimoto Y., Hampton L. L., Luo L. D., Wirth P. J., Thorgeirsson S. S. Low frequency of p53 gene mutation in tumors induced by aflatoxin B1 in nonhuman primates. Cancer Res. 1992 Feb 15;52(4):1044–1046. [PubMed] [Google Scholar]
  67. Fujiyama S., Iino S., Odoh K., Kuzuhara S., Watanabe H., Tanaka M., Mizuno K., Sato T. Time course of hepatitis A virus antibody titer after active and passive immunization. Hepatology. 1992 Jun;15(6):983–988. doi: 10.1002/hep.1840150602. [DOI] [PubMed] [Google Scholar]
  68. Fung J., Abu-Elmagd K., Jain A., Gordon R., Tzakis A., Todo S., Takaya S., Alessiani M., Demetris A., Bronster O. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc. 1991 Dec;23(6):2977–2983. [PMC free article] [PubMed] [Google Scholar]
  69. García-Pagán J. C., Feu F., Bosch J., Rodés J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med. 1991 May 15;114(10):869–873. doi: 10.7326/0003-4819-114-10-869. [DOI] [PubMed] [Google Scholar]
  70. Ghaffar Y. A., Fattah S. A., Kamel M., Badr R. M., Mahomed F. F., Strickland G. T. The impact of endemic schistosomiasis on acute viral hepatitis. Am J Trop Med Hyg. 1991 Dec;45(6):743–750. doi: 10.4269/ajtmh.1991.45.743. [DOI] [PubMed] [Google Scholar]
  71. Gimson A. E., Ramage J. K., Panos M. Z., Hayllar K., Harrison P. M., Williams R., Westaby D. Randomised trial of variceal banding ligation versus injection sclerotherapy for bleeding oesophageal varices. Lancet. 1993 Aug 14;342(8868):391–394. doi: 10.1016/0140-6736(93)92812-8. [DOI] [PubMed] [Google Scholar]
  72. Gimson A. E., Westaby D., Williams R. Endoscopic sclerotherapy in the management of gastric variceal haemorrhage. J Hepatol. 1991 Nov;13(3):274–278. doi: 10.1016/0168-8278(91)90068-m. [DOI] [PubMed] [Google Scholar]
  73. Giovannini M., Seitz J. F. Alcoolisation échoguidée percutanée des tumeurs hépatiques. Gastroenterol Clin Biol. 1992;16(2):126–130. [PubMed] [Google Scholar]
  74. Giovannini M., Seitz J. F., Rosello R., Gauthier A. Traitement de petites tumeurs hépatiques par injection per-cutanée échoguidée d'alcool absolu. Résultats chez 8 patients. Gastroenterol Clin Biol. 1989 Dec;13(12):974–977. [PubMed] [Google Scholar]
  75. Goldsmith R., Yarbough P. O., Reyes G. R., Fry K. E., Gabor K. A., Kamel M., Zakaria S., Amer S., Gaffar Y. Enzyme-linked immunosorbent assay for diagnosis of acute sporadic hepatitis E in Egyptian children. Lancet. 1992 Feb 8;339(8789):328–331. doi: 10.1016/0140-6736(92)91647-q. [DOI] [PubMed] [Google Scholar]
  76. Gores G. J., Steers J. L. Progress in orthotopic liver transplantation for hepatocellular carcinoma. Gastroenterology. 1993 Jan;104(1):317–320. doi: 10.1016/0016-5085(93)90868-d. [DOI] [PubMed] [Google Scholar]
  77. Haddad J., Deny P., Munz-Gotheil C., Ambrosini J. C., Trinchet J. C., Pateron D., Mal F., Callard P., Beaugrand M. Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease. Lancet. 1992 Feb 8;339(8789):321–323. doi: 10.1016/0140-6736(92)91645-O. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Hadler S. C., Francis D. P., Maynard J. E., Thompson S. E., Judson F. N., Echenberg D. F., Ostrow D. G., O'Malley P. M., Penley K. A., Altman N. L. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986 Jul 24;315(4):209–214. doi: 10.1056/NEJM198607243150401. [DOI] [PubMed] [Google Scholar]
  79. Halliday M. L., Kang L. Y., Zhou T. K., Hu M. D., Pan Q. C., Fu T. Y., Huang Y. S., Hu S. L. An epidemic of hepatitis A attributable to the ingestion of raw clams in Shanghai, China. J Infect Dis. 1991 Nov;164(5):852–859. doi: 10.1093/infdis/164.5.852. [DOI] [PubMed] [Google Scholar]
  80. Harrison P. M., Keays R., Bray G. P., Alexander G. J., Williams R. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet. 1990 Jun 30;335(8705):1572–1573. doi: 10.1016/0140-6736(90)91388-q. [DOI] [PubMed] [Google Scholar]
  81. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  82. Hoofnagle J. H., Di Bisceglie A. M., Waggoner J. G., Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology. 1993 Apr;104(4):1116–1121. doi: 10.1016/0016-5085(93)90281-g. [DOI] [PubMed] [Google Scholar]
  83. Hoofnagle J. H., Peters M., Mullen K. D., Jones D. B., Rustgi V., Di Bisceglie A., Hallahan C., Park Y., Meschievitz C., Jones E. A. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology. 1988 Nov;95(5):1318–1325. doi: 10.1016/0016-5085(88)90367-8. [DOI] [PubMed] [Google Scholar]
  84. Hoofnagle J. H. Type D (delta) hepatitis. JAMA. 1989 Mar 3;261(9):1321–1325. [PubMed] [Google Scholar]
  85. Hsia C. C., Kleiner D. E., Jr, Axiotis C. A., Di Bisceglie A., Nomura A. M., Stemmermann G. N., Tabor E. Mutations of p53 gene in hepatocellular carcinoma: roles of hepatitis B virus and aflatoxin contamination in the diet. J Natl Cancer Inst. 1992 Nov 4;84(21):1638–1641. doi: 10.1093/jnci/84.21.1638. [DOI] [PubMed] [Google Scholar]
  86. Hsu H. H., Wright T. L., Luba D., Martin M., Feinstone S. M., Garcia G., Greenberg H. B. Failure to detect hepatitis C virus genome in human secretions with the polymerase chain reaction. Hepatology. 1991 Nov;14(5):763–767. doi: 10.1002/hep.1840140504. [DOI] [PubMed] [Google Scholar]
  87. Hsu H. Y., Chang M. H., Lee C. Y., Chen J. S., Hsu H. C., Chen D. S. Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection. Hepatology. 1992 Mar;15(3):382–386. doi: 10.1002/hep.1840150304. [DOI] [PubMed] [Google Scholar]
  88. Hurie M. B., Mast E. E., Davis J. P. Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees. Pediatrics. 1992 Feb;89(2):269–273. [PubMed] [Google Scholar]
  89. Ikeda T., Lever A. M., Thomas H. C. Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life. Hepatology. 1986 Sep-Oct;6(5):962–965. doi: 10.1002/hep.1840060525. [DOI] [PubMed] [Google Scholar]
  90. Ildstad S. T., Wren S. M., Bluestone J. A., Barbieri S. A., Sachs D. H. Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance. J Exp Med. 1985 Jul 1;162(1):231–244. doi: 10.1084/jem.162.1.231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Itoh Y., Takai E., Ohnuma H., Kitajima K., Tsuda F., Machida A., Mishiro S., Nakamura T., Miyakawa Y., Mayumi M. A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proc Natl Acad Sci U S A. 1986 Dec;83(23):9174–9178. doi: 10.1073/pnas.83.23.9174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Kanematsu T., Furuta T., Takenaka K., Matsumata T., Yoshida Y., Nishizaki T., Hasuo K., Sugimachi K. A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology. 1989 Jul;10(1):98–102. doi: 10.1002/hep.1840100119. [DOI] [PubMed] [Google Scholar]
  93. Kasugai H., Kojima J., Tatsuta M., Okuda S., Sasaki Y., Imaoka S., Fujita M., Ishiguro S. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology. 1989 Oct;97(4):965–971. doi: 10.1016/0016-5085(89)91505-9. [DOI] [PubMed] [Google Scholar]
  94. Katayama K., Hayashi N., Sasaki Y., Kasahara A., Ueda K., Fusamoto H., Sato N., Chisaka O., Matsubara K., Kamada T. Detection of hepatitis B virus X gene protein and antibody in type B chronic liver disease. Gastroenterology. 1989 Oct;97(4):990–998. doi: 10.1016/0016-5085(89)91508-4. [DOI] [PubMed] [Google Scholar]
  95. Katayama T., Mazda T., Kikuchi S., Harada S., Matsuura Y., Chiba J., Ohba H., Saito I., Miyamura T. Improved serodiagnosis of non-A, non-B hepatitis by an assay detecting antibody to hepatitis C virus core antigen. Hepatology. 1992 Mar;15(3):391–394. doi: 10.1002/hep.1840150306. [DOI] [PubMed] [Google Scholar]
  96. Kino T., Hatanaka H., Miyata S., Inamura N., Nishiyama M., Yajima T., Goto T., Okuhara M., Kohsaka M., Aoki H. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987 Sep;40(9):1256–1265. doi: 10.7164/antibiotics.40.1256. [DOI] [PubMed] [Google Scholar]
  97. Kleber G., Sauerbruch T., Ansari H., Paumgartner G. Prediction of variceal hemorrhage in cirrhosis: a prospective follow-up study. Gastroenterology. 1991 May;100(5 Pt 1):1332–1337. [PubMed] [Google Scholar]
  98. Klein R. S., Freeman K., Taylor P. E., Stevens C. E. Occupational risk for hepatitis C virus infection among New York City dentists. Lancet. 1991 Dec 21;338(8782-8783):1539–1542. doi: 10.1016/0140-6736(91)92369-d. [DOI] [PubMed] [Google Scholar]
  99. Koda M., Okamoto K., Miyoshi Y., Kawasaki H. Hepatic vascular and bile duct injury after ethanol injection therapy for hepatocellular carcinoma. Gastrointest Radiol. 1992 Spring;17(2):167–169. doi: 10.1007/BF01888537. [DOI] [PubMed] [Google Scholar]
  100. Kress S., Jahn U. R., Buchmann A., Bannasch P., Schwarz M. p53 Mutations in human hepatocellular carcinomas from Germany. Cancer Res. 1992 Jun 1;52(11):3220–3223. [PubMed] [Google Scholar]
  101. König V., Bauditz J., Lobeck H., Lüsebrink R., Neuhaus P., Blumhardt G., Bechstein W. O., Neuhaus R., Steffen R., Hopf U. Hepatitis C virus reinfection in allografts after orthotopic liver transplantation. Hepatology. 1992 Nov;16(5):1137–1143. doi: 10.1002/hep.1840160506. [DOI] [PubMed] [Google Scholar]
  102. LaBerge J. M., Ring E. J., Lake J. R., Ferrell L. D., Doherty M. M., Gordon R. L., Roberts J. P., Peltzer M. Y., Ascher N. L. Transjugular intrahepatic portosystemic shunts: preliminary results in 25 patients. J Vasc Surg. 1992 Aug;16(2):258–267. doi: 10.1067/mva.1992.37161. [DOI] [PubMed] [Google Scholar]
  103. Lai C. L., Wu P. C., Chan G. C., Lok A. S., Lin H. J. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. 1988 Aug 1;62(3):479–483. doi: 10.1002/1097-0142(19880801)62:3<479::aid-cncr2820620306>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  104. Lane D. P. Cancer. A death in the life of p53. Nature. 1993 Apr 29;362(6423):786–787. doi: 10.1038/362786a0. [DOI] [PubMed] [Google Scholar]
  105. Lau J. Y., Sheron N., Morris A. G., Bomford A. B., Alexander G. J., Williams R. Interferon-alpha receptor expression and regulation in chronic hepatitis B virus infection. Hepatology. 1991 Feb;13(2):332–338. [PubMed] [Google Scholar]
  106. Lauchart W., Müller R., Pichlmayr R. Immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc. 1987 Feb;19(1 Pt 3):2387–2389. [PubMed] [Google Scholar]
  107. Leenders W. P., Glansbeek H. L., de Bruin W. C., Yap S. H. Binding of the major and large HBsAg to human hepatocytes and liver plasma membranes: putative external and internal receptors for infection and secretion of hepatitis B virus. Hepatology. 1990 Jul;12(1):141–147. doi: 10.1002/hep.1840120122. [DOI] [PubMed] [Google Scholar]
  108. Lemon S. M. Inactivated hepatitis A virus vaccines. Hepatology. 1992 Jun;15(6):1194–1197. doi: 10.1002/hep.1840150634. [DOI] [PubMed] [Google Scholar]
  109. Lemon S. M. Type A viral hepatitis. New developments in an old disease. N Engl J Med. 1985 Oct 24;313(17):1059–1067. doi: 10.1056/NEJM198510243131706. [DOI] [PubMed] [Google Scholar]
  110. Lisker-Melman M., Di Bisceglie A. M., Usala S. J., Weintraub B., Murray L. M., Hoofnagle J. H. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology. 1992 Jun;102(6):2155–2160. doi: 10.1016/0016-5085(92)90348-3. [DOI] [PubMed] [Google Scholar]
  111. Livraghi T., Bolondi L., Lazzaroni S., Marin G., Morabito A., Rapaccini G. L., Salmi A., Torzilli G. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer. 1992 Feb 15;69(4):925–929. doi: 10.1002/1097-0142(19920215)69:4<925::aid-cncr2820690415>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  112. Livraghi T., Festi D., Monti F., Salmi A., Vettori C. US-guided percutaneous alcohol injection of small hepatic and abdominal tumors. Radiology. 1986 Nov;161(2):309–312. doi: 10.1148/radiology.161.2.3020612. [DOI] [PubMed] [Google Scholar]
  113. Livraghi T. Percutaneous ethanol injection of hepatocellular carcinoma: survival after 3 years in 70 patients. Ital J Gastroenterol. 1992 Feb;24(2):72–74. [PubMed] [Google Scholar]
  114. Lok A. S., Novick D. M., Karayiannis P., Dunk A. A., Sherlock S., Thomas H. C. A randomized study of the effects of adenine arabinoside 5'-monophosphate (short or long courses) and lymphoblastoid interferon on hepatitis B virus replication. Hepatology. 1985 Nov-Dec;5(6):1132–1138. doi: 10.1002/hep.1840050612. [DOI] [PubMed] [Google Scholar]
  115. Lomas D. A., Evans D. L., Finch J. T., Carrell R. W. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992 Jun 18;357(6379):605–607. doi: 10.1038/357605a0. [DOI] [PubMed] [Google Scholar]
  116. Lucey M. R., Merion R. M., Henley K. S., Campbell D. A., Jr, Turcotte J. G., Nostrant T. T., Blow F. C., Beresford T. P. Selection for and outcome of liver transplantation in alcoholic liver disease. Gastroenterology. 1992 May;102(5):1736–1741. doi: 10.1016/0016-5085(92)91737-o. [DOI] [PubMed] [Google Scholar]
  117. Mac Mathuna P., Westaby D., Williams R. Taking the tension out of the portal system. An approach to the management of portal hypertension in the 1990s. Scand J Gastroenterol Suppl. 1990;175:131–145. doi: 10.3109/00365529009093137. [DOI] [PubMed] [Google Scholar]
  118. Machida A., Ohnuma H., Tsuda F., Munekata E., Tanaka T., Akahane Y., Okamoto H., Mishiro S. Two distinct subtypes of hepatitis C virus defined by antibodies directed to the putative core protein. Hepatology. 1992 Oct;16(4):886–891. doi: 10.1002/hep.1840160406. [DOI] [PubMed] [Google Scholar]
  119. Markus B. H., Duquesnoy R. J., Gordon R. D., Fung J. J., Vanek M., Klintmalm G., Bryan C., Van Thiel D., Starzl T. E. Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation. 1988 Sep;46(3):372–377. [PMC free article] [PubMed] [Google Scholar]
  120. Martin P., Munoz S. J., Friedman L. S. Liver transplantation for viral hepatitis: current status. Am J Gastroenterol. 1992 Apr;87(4):409–418. [PubMed] [Google Scholar]
  121. Mays E. T., Christopherson W. Hepatic tumors induced by sex steroids. Semin Liver Dis. 1984 May;4(2):147–157. doi: 10.1055/s-2008-1040654. [DOI] [PubMed] [Google Scholar]
  122. McCurry K. R., Baliga P., Merion R. M., Ham J. M., Lucey M. R., Beresford T. P., Turcotte J. G., Campbell D. A., Jr Resource utilization and outcome of liver transplantation for alcoholic cirrhosis. A case-control study. Arch Surg. 1992 Jul;127(7):772–777. doi: 10.1001/archsurg.1992.01420070024007. [DOI] [PubMed] [Google Scholar]
  123. McFarlane I. G., Smith H. M., Johnson P. J., Bray G. P., Vergani D., Williams R. Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet. 1990 Mar 31;335(8692):754–757. doi: 10.1016/0140-6736(90)90870-b. [DOI] [PubMed] [Google Scholar]
  124. McPeake J. R., O'Grady J. G., Zaman S., Portmann B., Wight D. G., Tan K. C., Calne R. Y., Williams R. Liver transplantation for primary hepatocellular carcinoma: tumor size and number determine outcome. J Hepatol. 1993 Jun;18(2):226–234. doi: 10.1016/s0168-8278(05)80250-8. [DOI] [PubMed] [Google Scholar]
  125. Melia W. M., Johnson P. J., Williams R. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep. 1987 Dec;71(12):1213–1216. [PubMed] [Google Scholar]
  126. Merkel C., Bolognesi M., Bellon S., Zuin R., Noventa F., Finucci G., Sacerdoti D., Angeli P., Gatta A. Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology. 1992 Mar;102(3):973–979. doi: 10.1016/0016-5085(92)90185-2. [DOI] [PubMed] [Google Scholar]
  127. Michel G., Ritter A., Gerken G., Meyer zum Büschenfelde K. H., Decker R., Manns M. P. Anti-GOR and hepatitis C virus in autoimmune liver diseases. Lancet. 1992 Feb 1;339(8788):267–269. doi: 10.1016/0140-6736(92)91332-3. [DOI] [PubMed] [Google Scholar]
  128. Michel M. L., Tiollais P. Structure and expression of the hepatitis B virus genome. Hepatology. 1987 Jan-Feb;7(1 Suppl):61S–63S. doi: 10.1002/hep.1840070711. [DOI] [PubMed] [Google Scholar]
  129. Mieli-Vergani G., Vergani D., Portmann B., White Y., Murray-Lyon I., Marigold J. H., Woolf I., Eddleston A. L., Williams R. Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg positive chronic liver disease. Gut. 1982 Dec;23(12):1029–1036. doi: 10.1136/gut.23.12.1029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Miller R. H., Kaneko S., Chung C. T., Girones R., Purcell R. H. Compact organization of the hepatitis B virus genome. Hepatology. 1989 Feb;9(2):322–327. doi: 10.1002/hep.1840090226. [DOI] [PubMed] [Google Scholar]
  131. Mills C. T., Lee E., Perrillo R. Relationship between histology, aminotransferase levels, and viral replication in chronic hepatitis B. Gastroenterology. 1990 Aug;99(2):519–524. doi: 10.1016/0016-5085(90)91035-5. [DOI] [PubMed] [Google Scholar]
  132. Misiani R., Bellavita P., Fenili D., Borelli G., Marchesi D., Massazza M., Vendramin G., Comotti B., Tanzi E., Scudeller G. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med. 1992 Oct 1;117(7):573–577. doi: 10.7326/0003-4819-117-7-573. [DOI] [PubMed] [Google Scholar]
  133. Mitsui T., Iwano K., Masuko K., Yamazaki C., Okamoto H., Tsuda F., Tanaka T., Mishiro S. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology. 1992 Nov;16(5):1109–1114. [PubMed] [Google Scholar]
  134. Mondelli M. U., Bortolotti F., Pontisso P., Rondanelli E. G., Williams R., Realdi G., Alberti A., Eddleston A. L. Definition of hepatitis B virus (HBV)-specific target antigens recognized by cytotoxic T cells in acute HBV infection. Clin Exp Immunol. 1987 May;68(2):242–250. [PMC free article] [PubMed] [Google Scholar]
  135. Mondelli M., Vergani G. M., Alberti A., Vergani D., Portmann B., Eddleston A. L., Williams R. Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol. 1982 Dec;129(6):2773–2778. [PubMed] [Google Scholar]
  136. Nagasue N., Yukaya H., Hamada T., Hirose S., Kanashima R., Inokuchi K. The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer. 1984 Oct 1;54(7):1461–1465. doi: 10.1002/1097-0142(19841001)54:7<1461::aid-cncr2820540740>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  137. Naoumov N. V., Schneider R., Grötzinger T., Jung M. C., Miska S., Pape G. R., Will H. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology. 1992 Feb;102(2):538–543. doi: 10.1016/0016-5085(92)90101-4. [DOI] [PubMed] [Google Scholar]
  138. Naumov N. V., Mondelli M., Alexander G. J., Tedder R. S., Eddleston A. L., Williams R. Relationship between expression of hepatitis B virus antigens in isolated hepatocytes and autologous lymphocyte cytotoxicity in patients with chronic hepatitis B virus infection. Hepatology. 1984 Jan-Feb;4(1):63–68. doi: 10.1002/hep.1840040111. [DOI] [PubMed] [Google Scholar]
  139. Naveau S., Bedossa P., Poynard T., Mory B., Chaput J. C. Portal hypertensive colopathy. A new entity. Dig Dis Sci. 1991 Dec;36(12):1774–1781. doi: 10.1007/BF01296624. [DOI] [PubMed] [Google Scholar]
  140. Neurath A. R., Strick N., Sproul P. Search for hepatitis B virus cell receptors reveals binding sites for interleukin 6 on the virus envelope protein. J Exp Med. 1992 Feb 1;175(2):461–469. doi: 10.1084/jem.175.2.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  141. Neurath A. R., Strick N., Sproul P. Search for hepatitis B virus cell receptors reveals binding sites for interleukin 6 on the virus envelope protein. J Exp Med. 1992 Feb 1;175(2):461–469. doi: 10.1084/jem.175.2.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Nevens F., Goubau P., Van Eyken P., Desmyter J., Desmet V., Fevery J. Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha. Liver. 1993 Feb;13(1):15–19. doi: 10.1111/j.1600-0676.1993.tb00599.x. [DOI] [PubMed] [Google Scholar]
  143. Nishiguchi S., Kuroki T., Ueda T., Fukuda K., Takeda T., Nakajima S., Shiomi S., Kobayashi K., Otani S., Hayashi N. Detection of hepatitis C virus antibody in the absence of viral RNA in patients with autoimmune hepatitis. Ann Intern Med. 1992 Jan 1;116(1):21–25. doi: 10.7326/0003-4819-116-1-21. [DOI] [PubMed] [Google Scholar]
  144. O'Grady J. G., Alexander G. J., Sutherland S., Donaldson P. T., Harvey F., Portmann B., Calne R. Y., Williams R. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet. 1988 Aug 6;2(8606):302–305. doi: 10.1016/s0140-6736(88)92356-2. [DOI] [PubMed] [Google Scholar]
  145. O'Grady J. G., Polson R. J., Rolles K., Calne R. Y., Williams R. Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg. 1988 Apr;207(4):373–379. doi: 10.1097/00000658-198804000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. O'Grady J. G., Smith H. M., Davies S. E., Daniels H. M., Donaldson P. T., Tan K. C., Portmann B., Alexander G. J., Williams R. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol. 1992 Jan;14(1):104–111. doi: 10.1016/0168-8278(92)90138-f. [DOI] [PubMed] [Google Scholar]
  147. Ohishi H., Uchida H., Yoshimura H., Ohue S., Ueda J., Katsuragi M., Matsuo N., Hosogi Y. Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents. Radiology. 1985 Jan;154(1):25–29. doi: 10.1148/radiology.154.1.2981114. [DOI] [PubMed] [Google Scholar]
  148. Ohnishi S., Murakami T., Moriyama T., Mitamura K., Imawari M. Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding noncancerous liver tissue. Hepatology. 1986 May-Jun;6(3):440–443. doi: 10.1002/hep.1840060320. [DOI] [PubMed] [Google Scholar]
  149. Okuda K., Ohtsuki T., Obata H., Tomimatsu M., Okazaki N., Hasegawa H., Nakajima Y., Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985 Aug 15;56(4):918–928. doi: 10.1002/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  150. Onji M., Lever A. M., Saito I., Thomas H. C. Defective response to interferons in cells transfected with the hepatitis B virus genome. Hepatology. 1989 Jan;9(1):92–96. doi: 10.1002/hep.1840090115. [DOI] [PubMed] [Google Scholar]
  151. Ottobrelli A., Marzano A., Smedile A., Recchia S., Salizzoni M., Cornu C., Lamy M. E., Otte J. B., De Hemptinne B., Geubel A. Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology. 1991 Dec;101(6):1649–1655. doi: 10.1016/0016-5085(91)90404-9. [DOI] [PubMed] [Google Scholar]
  152. Ou J. H., Laub O., Rutter W. J. Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1578–1582. doi: 10.1073/pnas.83.6.1578. [DOI] [PMC free article] [PubMed] [Google Scholar]
  153. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet. 1991 Nov 30;338(8779):1356–1359. doi: 10.1016/0140-6736(91)92236-u. [DOI] [PubMed] [Google Scholar]
  155. Pagliaro L., D'Amico G., Sörensen T. I., Lebrec D., Burroughs A. K., Morabito A., Tiné F., Politi F., Traina M. Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med. 1992 Jul 1;117(1):59–70. doi: 10.7326/0003-4819-117-1-59. [DOI] [PubMed] [Google Scholar]
  156. Paliard P., Clément G., Saez S., Chabal J., Partensky C. Traitement du carcinome hépato-cellulaire par le tamoxifène. Gastroenterol Clin Biol. 1984 Aug-Sep;8(8-9):680–681. [PubMed] [Google Scholar]
  157. Palmer R. M., Ashton D. S., Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988 Jun 16;333(6174):664–666. doi: 10.1038/333664a0. [DOI] [PubMed] [Google Scholar]
  158. Panés J., Bordas J. M., Piqué J. M., Bosch J., García-Pagán J. C., Feu F., Casadevall M., Terés J., Rodés J. Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Gastroenterology. 1992 Dec;103(6):1875–1882. doi: 10.1016/0016-5085(92)91447-c. [DOI] [PubMed] [Google Scholar]
  159. Papo T., Marcellin P., Bernuau J., Durand F., Poynard T., Benhamou J. P. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med. 1992 Jan 1;116(1):51–53. doi: 10.7326/0003-4819-116-1-51. [DOI] [PubMed] [Google Scholar]
  160. Perarnau J. M., Noeldge G., Rössle M. Anastomose porto-cave intra-hépatique par voie transjugulaire. Utilisation de l'endoprothèse de Palmaz. Presse Med. 1991 Nov 9;20(36):1770–1772. [PubMed] [Google Scholar]
  161. Pereira B. J., Milford E. L., Kirkman R. L., Quan S., Sayre K. R., Johnson P. J., Wilber J. C., Levey A. S. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med. 1992 Sep 24;327(13):910–915. doi: 10.1056/NEJM199209243271302. [DOI] [PubMed] [Google Scholar]
  162. Perrillo R. P., Schiff E. R., Davis G. L., Bodenheimer H. C., Jr, Lindsay K., Payne J., Dienstag J. L., O'Brien C., Tamburro C., Jacobson I. M. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 1990 Aug 2;323(5):295–301. doi: 10.1056/NEJM199008023230503. [DOI] [PubMed] [Google Scholar]
  163. Pizcueta P., Piqué J. M., Fernández M., Bosch J., Rodés J., Whittle B. J., Moncada S. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology. 1992 Dec;103(6):1909–1915. doi: 10.1016/0016-5085(92)91451-9. [DOI] [PubMed] [Google Scholar]
  164. Pontisso P., Poon M. C., Tiollais P., Brechot C. Detection of hepatitis B virus DNA in mononuclear blood cells. Br Med J (Clin Res Ed) 1984 May 26;288(6430):1563–1566. doi: 10.1136/bmj.288.6430.1563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  165. Poterucha J. J., Rakela J., Lumeng L., Lee C. H., Taswell H. F., Wiesner R. H. Diagnosis of chronic hepatitis C after liver transplantation by the detection of viral sequences with polymerase chain reaction. Hepatology. 1992 Jan;15(1):42–45. doi: 10.1002/hep.1840150109. [DOI] [PubMed] [Google Scholar]
  166. Powell L. W., Summers K. M., Board P. G., Axelsen E., Webb S., Halliday J. W. Expression of hemochromatosis in homozygous subjects. Implications for early diagnosis and prevention. Gastroenterology. 1990 Jun;98(6):1625–1632. doi: 10.1016/0016-5085(90)91100-k. [DOI] [PubMed] [Google Scholar]
  167. Prescott L. F., Illingworth R. N., Critchley J. A., Stewart M. J., Adam R. D., Proudfoot A. T. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J. 1979 Nov 3;2(6198):1097–1100. doi: 10.1136/bmj.2.6198.1097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  168. Puoti M., Zonaro A., Ravaggi A., Marin M. G., Castelnuovo F., Cariani E. Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection. Hepatology. 1992 Oct;16(4):877–881. doi: 10.1002/hep.1840160404. [DOI] [PubMed] [Google Scholar]
  169. Rakela J. Hepatitis C viral infection in liver transplant patients: how bad is it really? Gastroenterology. 1992 Jul;103(1):338–339. doi: 10.1016/0016-5085(92)91134-p. [DOI] [PubMed] [Google Scholar]
  170. Reynès M., Zignego L., Samuel D., Fabiani B., Gugenheim J., Tricottet V., Brechot C., Bismuth H. Graft hepatitis delta virus reinfection after orthotopic liver transplantation in HDV cirrhosis. Transplant Proc. 1989 Feb;21(1 Pt 2):2424–2425. [PubMed] [Google Scholar]
  171. Rigo G. P., Merighi A., Chahin N. J., Mastronardi M., Codeluppi P. L., Ferrari A., Armocida C., Zanasi G., Cristani A., Cioni G. A prospective study of the ability of three endoscopic classifications to predict hemorrhage from esophageal varices. Gastrointest Endosc. 1992 Jul-Aug;38(4):425–429. doi: 10.1016/s0016-5107(92)70470-2. [DOI] [PubMed] [Google Scholar]
  172. Ring E. J., Lake J. R., Roberts J. P., Gordon R. L., LaBerge J. M., Read A. E., Sterneck M. R., Ascher N. L. Using transjugular intrahepatic portosystemic shunts to control variceal bleeding before liver transplantation. Ann Intern Med. 1992 Feb 15;116(4):304–309. doi: 10.7326/0003-4819-116-4-304. [DOI] [PubMed] [Google Scholar]
  173. Rizzetto M., Verme G. Delta hepatitis--present status. J Hepatol. 1985;1(2):187–193. doi: 10.1016/s0168-8278(85)80766-2. [DOI] [PubMed] [Google Scholar]
  174. Roth D., Fernandez J. A., Babischkin S., De Mattos A., Buck B. E., Quan S., Olson L., Burke G. W., Nery J. R., Esquenazi V. Detection of hepatitis C virus infection among cadaver organ donors: evidence for low transmission of disease. Ann Intern Med. 1992 Sep 15;117(6):470–475. doi: 10.7326/0003-4819-117-6-470. [DOI] [PubMed] [Google Scholar]
  175. Russell P. S. Some immunological considerations in liver transplantation. Hepatology. 1984 Jan-Feb;4(1 Suppl):76S–78S. doi: 10.1002/hep.1840040720. [DOI] [PubMed] [Google Scholar]
  176. Rösch J., Antonovic R., Dotter C. T. Transjugular approach to the liver, biliary system, and portal circulation. Am J Roentgenol Radium Ther Nucl Med. 1975 Nov;125(3):602–608. doi: 10.2214/ajr.125.3.602. [DOI] [PubMed] [Google Scholar]
  177. Rössle M., Haag K. Interventional treatment of portal hypertension. Dig Dis. 1992;10 (Suppl 1):94–102. doi: 10.1159/000171395. [DOI] [PubMed] [Google Scholar]
  178. Sachs D. H. Specific transplantation tolerance. N Engl J Med. 1991 Oct 24;325(17):1240–1242. doi: 10.1056/NEJM199110243251708. [DOI] [PubMed] [Google Scholar]
  179. Sanchez-Urdazpal L., Gores G. J., Ward E. M., Maus T. P., Wahlstrom H. E., Moore S. B., Wiesner R. H., Krom R. A. Ischemic-type biliary complications after orthotopic liver transplantation. Hepatology. 1992 Jul;16(1):49–53. doi: 10.1002/hep.1840160110. [DOI] [PubMed] [Google Scholar]
  180. Santantonio T., Jung M. C., Schneider R., Pastore G., Pape G. R., Will H. Selection for a pre-C stop codon mutation in a hepatitis B virus variant with a pre-C initiation codon mutation during interferon treatment. J Hepatol. 1991 Nov;13(3):368–371. doi: 10.1016/0168-8278(91)90083-n. [DOI] [PubMed] [Google Scholar]
  181. Scheuer P. J., Ashrafzadeh P., Sherlock S., Brown D., Dusheiko G. M. The pathology of hepatitis C. Hepatology. 1992 Apr;15(4):567–571. doi: 10.1002/hep.1840150402. [DOI] [PubMed] [Google Scholar]
  182. Schrier R. W., Arroyo V., Bernardi M., Epstein M., Henriksen J. H., Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988 Sep-Oct;8(5):1151–1157. doi: 10.1002/hep.1840080532. [DOI] [PubMed] [Google Scholar]
  183. Scorsone K. A., Zhou Y. Z., Butel J. S., Slagle B. L. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res. 1992 Mar 15;52(6):1635–1638. [PubMed] [Google Scholar]
  184. Selby R., Starzl T. E., Yunis E., Brown B. I., Kendall R. S., Tzakis A. Liver transplantation for type IV glycogen storage disease. N Engl J Med. 1991 Jan 3;324(1):39–42. doi: 10.1056/NEJM199101033240107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  185. Shah G., Demetris A. J., Gavaler J. S., Lewis J. H., Todo S., Starzl T. E., Van Thiel D. H. Incidence, prevalence, and clinical course of hepatitis C following liver transplantation. Gastroenterology. 1992 Jul;103(1):323–329. doi: 10.1016/0016-5085(92)91130-v. [DOI] [PMC free article] [PubMed] [Google Scholar]
  186. Sheron N., Lau J., Daniels H., Goka J., Eddleston A., Alexander G. J., Williams R. Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection. J Hepatol. 1991 Mar;12(2):241–245. doi: 10.1016/0168-8278(91)90945-8. [DOI] [PubMed] [Google Scholar]
  187. Shiina S., Tagawa K., Unuma T., Fujino H., Uta Y., Niwa Y., Hata Y., Komatsu Y., Shiratori Y., Terano A. Percutaneous ethanol injection therapy of hepatocellular carcinoma: analysis of 77 patients. AJR Am J Roentgenol. 1990 Dec;155(6):1221–1226. doi: 10.2214/ajr.155.6.2173384. [DOI] [PubMed] [Google Scholar]
  188. Shindo M., Di Bisceglie A. M., Hoofnagle J. H. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology. 1992 Jun;15(6):1013–1016. doi: 10.1002/hep.1840150607. [DOI] [PubMed] [Google Scholar]
  189. Simon M., Bourel M., Fauchet R., Genetet B. Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis. Gut. 1976 May;17(5):332–334. doi: 10.1136/gut.17.5.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  190. Sogni P., Moreau R., Ohsuga M., Cailmail S., Oberti F., Hadengue A., Pussard E., Lebrec D. Evidence for normal nitric oxide-mediated vasodilator tone in conscious rats with cirrhosis. Hepatology. 1992 Oct;16(4):980–983. doi: 10.1002/hep.1840160421. [DOI] [PubMed] [Google Scholar]
  191. Sorrell M. F., Donovan J. P., Shaw B. W., Jr Transplantation in the alcoholic: a stalking horse for a larger problem. Gastroenterology. 1992 May;102(5):1806–1808. doi: 10.1016/0016-5085(92)91748-s. [DOI] [PubMed] [Google Scholar]
  192. Stark M. E., Szurszewski J. H. Role of nitric oxide in gastrointestinal and hepatic function and disease. Gastroenterology. 1992 Dec;103(6):1928–1949. doi: 10.1016/0016-5085(92)91454-c. [DOI] [PubMed] [Google Scholar]
  193. Starzl T. E., Demetris A. J., Murase N., Ildstad S., Ricordi C., Trucco M. Cell migration, chimerism, and graft acceptance. Lancet. 1992 Jun 27;339(8809):1579–1582. doi: 10.1016/0140-6736(92)91840-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  194. Starzl T. E., Demetris A. J., Trucco M., Ricordi C., Ildstad S., Terasaki P. I., Murase N., Kendall R. S., Kocova M., Rudert W. A. Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med. 1993 Mar 18;328(11):745–749. doi: 10.1056/NEJM199303183281101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  195. Stiegmann G. V., Goff J. S., Michaletz-Onody P. A., Korula J., Lieberman D., Saeed Z. A., Reveille R. M., Sun J. H., Lowenstein S. R. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med. 1992 Jun 4;326(23):1527–1532. doi: 10.1056/NEJM199206043262304. [DOI] [PubMed] [Google Scholar]
  196. Stone M. J., Klintmalm G. B., Polter D., Husberg B. S., Mennel R. G., Ramsay M. A., Flemens E. R., Goldstein R. M. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology. 1993 Jan;104(1):196–202. doi: 10.1016/0016-5085(93)90852-4. [DOI] [PubMed] [Google Scholar]
  197. Stuart J. M., Majeed F. A., Cartwright K. A., Room R., Parry J. V., Perry K. R., Begg N. T. Salivary antibody testing in a school outbreak of hepatitis A. Epidemiol Infect. 1992 Aug;109(1):161–166. [PMC free article] [PubMed] [Google Scholar]
  198. Sugitani M., Inchauspé G., Shindo M., Prince A. M. Sensitivity of serological assays to identify blood donors with hepatitis C viraemia. Lancet. 1992 Apr 25;339(8800):1018–1019. doi: 10.1016/0140-6736(92)90538-e. [DOI] [PubMed] [Google Scholar]
  199. Takayasu K., Shima Y., Muramatsu Y., Moriyama N., Yamada T., Makuuchi M., Hasegawa H., Hirohashi S. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology. 1987 May;163(2):345–351. doi: 10.1148/radiology.163.2.3031724. [DOI] [PubMed] [Google Scholar]
  200. Tanoue K., Hashizume M., Wada H., Ohta M., Kitano S., Sugimachi K. Effects of endoscopic injection sclerotherapy on portal hypertensive gastropathy: a prospective study. Gastrointest Endosc. 1992 Sep-Oct;38(5):582–585. doi: 10.1016/s0016-5107(92)70522-7. [DOI] [PubMed] [Google Scholar]
  201. Thieme T., Yoshihara P., Piacentini S., Beller M. Clinical evaluation of oral fluid samples for diagnosis of viral hepatitis. J Clin Microbiol. 1992 May;30(5):1076–1079. doi: 10.1128/jcm.30.5.1076-1079.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  202. Tinè F., Magrin S., Craxì A., Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol. 1991 Sep;13(2):192–199. doi: 10.1016/0168-8278(91)90814-r. [DOI] [PubMed] [Google Scholar]
  203. Trey C., Davidson C. S. The management of fulminant hepatic failure. Prog Liver Dis. 1970;3:282–298. [PubMed] [Google Scholar]
  204. Trinchet J. C., Roudil F., Vaysse J., Beaugrand M. Effets d'une association tamoxifène-noréthistérone chez 16 malades atteints de carcinome hépatocellulaire. Gastroenterol Clin Biol. 1985 May;9(5):455–456. [PubMed] [Google Scholar]
  205. Twu J. S., Lee C. H., Lin P. M., Schloemer R. H. Hepatitis B virus suppresses expression of human beta-interferon. Proc Natl Acad Sci U S A. 1988 Jan;85(1):252–256. doi: 10.1073/pnas.85.1.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  206. Vallance P., Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet. 1991 Mar 30;337(8744):776–778. doi: 10.1016/0140-6736(91)91384-7. [DOI] [PubMed] [Google Scholar]
  207. Van Ruiswyk J., Byrd J. C. Efficacy of prophylactic sclerotherapy for prevention of a first variceal hemorrhage. Gastroenterology. 1992 Feb;102(2):587–597. doi: 10.1016/0016-5085(92)90107-a. [DOI] [PubMed] [Google Scholar]
  208. Van der Poel C. L., Cuypers H. T., Reesink H. W., Weiner A. J., Quan S., Di Nello R., Van Boven J. J., Winkel I., Mulder-Folkerts D., Exel-Oehlers P. J. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet. 1991 Feb 9;337(8737):317–319. doi: 10.1016/0140-6736(91)90942-i. [DOI] [PubMed] [Google Scholar]
  209. Vento S., Hegarty J. E., Alberti A., O'Brien C. J., Alexander G. J., Eddleston A. L., Williams R. T lymphocyte sensitization to HBcAg and T cell-mediated unresponsiveness to HBsAg in hepatitis B virus-related chronic liver disease. Hepatology. 1985 Mar-Apr;5(2):192–197. doi: 10.1002/hep.1840050206. [DOI] [PubMed] [Google Scholar]
  210. Vinel J. P., Scotto J. M., Levade M., Teisseire R., Cassigneul J., Cales P., Voigt J. J., Pascal J. P. Embolisation des varices oesophagiennes par voie transjugulaire dans les hémorragies digestives graves du cirrhotique. Etude prospective de 83 patients. Gastroenterol Clin Biol. 1985 Nov;9(11):814–818. [PubMed] [Google Scholar]
  211. Vlavianos P., Gimson A. E., Westaby D., Williams R. Balloon tamponade in variceal bleeding: use and misuse. BMJ. 1989 Apr 29;298(6681):1158–1158. doi: 10.1136/bmj.298.6681.1158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  212. Walker S., Kreichgauer H. P., Bode J. C. Terlipressin vs. somatostatin in bleeding esophageal varices: a controlled, double-blind study. Hepatology. 1992 Jun;15(6):1023–1030. doi: 10.1002/hep.1840150609. [DOI] [PubMed] [Google Scholar]
  213. Wang T. F., Lee F. Y., Tsai Y. T., Lee S. D., Wang S. S., Hsia H. C., Lin W. J., Lin H. C., Lai K. H., Chan C. Y. Relationship of portal pressure, anorectal varices and hemorrhoids in cirrhotic patients. J Hepatol. 1992 May;15(1-2):170–173. doi: 10.1016/0168-8278(92)90031-j. [DOI] [PubMed] [Google Scholar]
  214. Weber J. L., May P. E. Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet. 1989 Mar;44(3):388–396. [PMC free article] [PubMed] [Google Scholar]
  215. Werzberger A., Mensch B., Kuter B., Brown L., Lewis J., Sitrin R., Miller W., Shouval D., Wiens B., Calandra G. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med. 1992 Aug 13;327(7):453–457. doi: 10.1056/NEJM199208133270702. [DOI] [PubMed] [Google Scholar]
  216. Wolfsen H. C., Porayko M. K., Hughes R. H., Gostout C. J., Krom R. A., Wiesner R. H. Role of endoscopic retrograde cholangiopancreatography after orthotopic liver transplantation. Am J Gastroenterol. 1992 Aug;87(8):955–960. [PubMed] [Google Scholar]
  217. Wright T. L., Donegan E., Hsu H. H., Ferrell L., Lake J. R., Kim M., Combs C., Fennessy S., Roberts J. P., Ascher N. L. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology. 1992 Jul;103(1):317–322. doi: 10.1016/0016-5085(92)91129-r. [DOI] [PubMed] [Google Scholar]
  218. Yagihashi A., Kobayashi M., Noguchi K., Konno A., Yoshida Y., Terasawa K., Starzl T. E., Iwaki Y. HLA matching effect in liver transplantation. Transplant Proc. 1992 Dec;24(6):2432–2433. [PMC free article] [PubMed] [Google Scholar]
  219. Yang N. Y., Yu P. H., Mao Z. X., Chen N. L., Chai S. A., Mao J. S. Inapparent infection of hepatitis A virus. Am J Epidemiol. 1988 Mar;127(3):599–604. [PubMed] [Google Scholar]
  220. Yokoyama I., Sheahan D. G., Carr B., Kakizoe S., Selby R., Tzakis A. G., Todo S., Iwatsuki S., Starzl T. E. Clinicopathologic factors affecting patient survival and tumor recurrence after orthotopic liver transplantation for hepatocellular carcinoma. Transplant Proc. 1991 Aug;23(4):2194–2196. [PubMed] [Google Scholar]
  221. Zachoval R., Abb J., Zachoval V., Eisenburg J., Pape G. R., Paumgartner G., Deinhardt F. Interferon alpha in hepatitis type B and non-A, non-B. Defective production by peripheral blood mononuclear cells in chronic infection and development of serum interferon in acute disease. J Hepatol. 1988 Jun;6(3):364–368. doi: 10.1016/s0168-8278(88)80055-2. [DOI] [PubMed] [Google Scholar]
  222. Zemel G., Becker G. J., Bancroft J. W., Benenati J. F., Katzen B. T. Technical advances in transjugular intrahepatic portosystemic shunts. Radiographics. 1992 Jul;12(4):615–624. doi: 10.1148/radiographics.12.4.1636029. [DOI] [PubMed] [Google Scholar]
  223. de Martino M., Rossi M. E., Muccioli A. T., Resti M., Vierucci A. Interference of hepatitis B virus surface antigen with natural killer cell function. Clin Exp Immunol. 1985 Jul;61(1):90–95. [PMC free article] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES